Effectiveness [and Implementation]
of a Pragmatic Direct-Mail
Colorectal Cancer Screening
Program in Safety Net Clinics



Amanda Petrik, Sr. Research Associate

The Center for Health Research



Research Team

The Center for Health Research, Kaiser Permanente Northwest Portland, Oregon, USA

Kaiser Permanente Center for Health Research, Portland, OR USA

- Gloria D. Coronado, PhD, PI
- Erin M. Keast, MS, Analyst
- William M. Vollmer, PhD, Statistician Co-I
- Richard Meenan, PhD, Co-I
- Jennifer Schneider, MA, Co-I

Center for Global Health, National Cancer Institute, Rockville MD USA

Steve H. Taplin, MD, MPH

Kaiser Permanente Washington, Research Institute, Seattle, WA USA

Beverly B. Green, MD, MPH⁴

OCHIN, Portland, OR USA

Scott Fields, MD





Key Points

- How effective is a direct-mail fecal testing program when implemented in busy community clinic practices as part of standard care?
- To report the effectiveness and level of implementation of an electronic health record (EHR)— embedded program to directly mail fecal tests to patients due for colorectal cancer screening.



Background

- The US Preventive Services Task Force recommends routine colorectal cancer screening for individuals aged 50 – 75.
- Programs that directly mail fecal tests to patients' homes have been shown to improve rates of colorectal cancer screening in various clinical settings.
- Little is known about the effectiveness of such programs when implemented in community health centers as part of standard care.




Explanatory study vs. pragmatic study

Explanatory Study

Eligible population Exclusions, non-response, etc. Efficacy (among a defined subset)

Pragmatic Study



Eligible population

etc.

Effectiveness (among a broad subset)



Design, Setting, Participants

- Pragmatic clinical study
 - Eligibility, 50-75, screening appropriate
- 8 federally qualified health centers
 - 26 clinics (13 clinics randomized to 2 arms)
 - 41,000 patients
- Year 01 intervention interval: February 4, 2014 February 3, 2015
- Year 01 evaluation interval: February 4, 2014 -- August 3, 2015



STOP CRC intervention

EMR tools in Reporting Workbench, driven by Health Maintenance; Step-wise exclusions for:

- Invalid address
- Self-reported prior screening
- Completion of CRC screening
 Improvement cycle (e.g. Plan-Do-Study-Act)

Step 1: Mail Introductory letter

Step 2: Mail FIT kit

Step 3: Mail Reminder Postcard



Main outcomes and measures

- Effectiveness: Clinic-level proportions of adults eligible for colorectal cancer screening during the intervention interval who completed fecal testing, and secondarily any CRC screening;
- Implementation: Clinic-level proportions of eligible adults who were mailed a fecal test as part of the program



Baseline clinic-level characteristics of eligible adults in analysis sample (n = 41,193)

	Intervention clinics		Usual care clinics	
	(n = 13)		(n = 13)	
	Median clinic % ^a	(range)	Median clinic % ^a	(range)
Age (50-64)	80	(73-85)	83	(72-88)
Gender (Female)	44	(38-56)	45	(35-51)
Ethnicity (% Hispanic)	8	(1-33)	15	(2-36)
Language				
English	90	(41-99)	86	(53-99)
Spanish	4	(0-26)	12	(1-31)
Other	0	(0-48)	1	(0-18)
Insurance status				
Medicaid	36	(20-51)	35	(25-54)
Medicare	24	(20-37)	23	(15-36)
Uninsured	26	(3-40)	27	(2-38)
Commercial	10	(1-49)	11	(1-39)
Federal poverty level				
<100%	47	(13-61)	45	(19-64)
100-150%	19	(6-31)	18	(14-24)
151 - 200%	9	(2-14)	9	(5-13)
201+	10	(3-26)	10	(2-36)
Unknown	17	(3-76)	21	(1-36)

Colorectal cancer screening completion, by intervention and usual care arm


	Intervention Usual Care		Difference		p value ^a
			Mean, %	95% CI	
Primary dataset					
No. eligible	21,134	20,059			
Returned FIT, % b	13.8	9.9	3.8	(-0.8, 8.5)	0.105
Completed any CRC	18.5	14.0	4.5	(0.1, 8.9)	0.046
screening, % (EHR data) b					
agged dataset c					
No. eligible	15,763	14,904			
Returned FIT, % b	18.1	12.4	5.6	(0.8, 10.4)	0.026
Completed any CRC	21.6	15.9	5.8	(1.4, 10.1)	0.014
screening, % (EHR data) b					

^a 2-sided significance level based on generalized estimating equation (GEE) models and use observed distribution of health centers, gender, and mean age (59) for full cohort b probabilities and differences based on same GEE models



^c delays participant accrual for four months

Colorectal cancer screening completion, by intervention and usual care arm





PRIMARY DATASET


		┌── % Adults	who comple	eted FIT —
HEALTH CENTERS	MAILED FIT %	INTERVENTION %	USUAL CARE	ABSOLUTE DIFFERENCE %
HC1	68.2	20.3	2.7	17.6
HC2	48.4	21.3	11.7	9.6
НС3	38.6	22.9	21.3	1.6
HC4	27.7	14.1	6.8	7.3
HC5	21.9	4.3	11.7	-7.4
HC6	18.0	12.3	11.1	1.2
HC7	16.6	6.0	8.9	-2.9
HC8	6.5	7.8	15.0	-7.2
ALL	29.9	14.3	10.7	3.6

LAGGED DATASET

HEALTH CENTERS	MAILED FIT %	% Adults INTERVENTION %	who comple usual care %	eted FIT —— ABSOLUTE DIFFERENCE %
HC1	81.7	24.6	3.4	21.2
HC2	59.3	23.3	12.7	10.6
НС3	43.3	27.1	21.9	5.2
HC4	42.1	15.7	8.0	7.7
HC5	37.1	7.2	18.9	-11.7
HC6	26.3	17.3	13.7	3.6
НС7	33.2	9.2	11.2	-2.0
HC8	38.5	11.6	17.0	-5.4
ALL	21.0	17.5	12.7	4.8

Implementation and effectiveness in primary and lagged analysis, by health center

Absolute difference % who completed FIT





Conclusions

- An efficacious CRC screening strategy can be effective in a real-world, community health center setting
- Barriers to implementation limited overall effectiveness
- After accounting for implementation delays, which were experienced by all participating clinics, we found 5.6% higher FIT completion rates in clinics that received tools and training for a direct-mail FIT program
- Low rates of implementation were common and were associated with low levels of effectiveness.
- Mail-based fecal screening programs can have clinical impact when integrated into clinical workflows
- Emphasizes the need to identify additional strategies to support program implementation in low-resource health centers.



It takes a village:

- CHR research team:
 - Gloria Coronado, PhD
 - Bill Vollmer, PhD
 - Amanda Petrik MS
 - Jennifer Rivelli, MA
 - Jennifer Schneider, MA
 - Jamie Thompson, MPH
 - Erin Keast, MS
 - Sally Retecki, MBA
 - Rich Meenan, PhD
 - Sacha Reich

- OCHIN:
 - Scott Fields, MD
 - Jon Puro, MS
 - Thuy Le, MS
 - Joy Woodall, MA
 - Lori Jacob, MS
- Group Health:
 - Beverly Green, MD, MPH
- NIH:
 - Stephen Taplin, MD, MPH
 - Jerry Suls, PhD
 - Erica Breslau, PhD
- STOP CRC Advisory Board

Research reported in this presentation was supported by the National Cancer Institute of the National Institutes of Health under **Award Number** UH3CA188640. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The study sponsor had no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.

